Skip to main content
SpringerLink
Log in

Sevelamer is an Effective Drug in Treating Hyperphosphatemia Due to Tumor Lysis Syndrome in Children: A Developing World Experience

  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

We report here a study on efficacy of sevelamer hydrochloride in treating hyperphosphatemia due to tumor lysis syndrome (TLS) in a developing world setting. Twenty one children with hyperphosphatemia due to TLS were included. All received hyper-hydration, allopurinol and sevelamer. Efficacy was assessed by decrease in serum phosphate level, calcium-phosphate product and TLS score as per Cairo Bishop definition. Four children who underwent dialysis were excluded from analysis. Among the remaining 17 patients with hyperphosphatemia, laboratory TLS was recorded in 15 patients and clinical TLS in five. Sevelamer was given according to weight, most often 400 mg twice to thrice daily. Mean phosphatemia decreased from 8.3 ± 3.0 to 6.7 ± 2.1 mg/dl within 24 h of starting sevelamer (p = 0.02), 6.0 ± 2.1 mg/dl at 48 h, 4.9 ± 1.5 mg/dl at 72 h and 4.39 ± 1.7 mg/dl at 96 h. TLS was corrected in 72 h in 14 patients, 96 h in 1 and 120 h in another patient. Mean calcium-phosphate product decreased from 63.0 ± 14.0 to 49.2 ± 9.7 mg/dl (p = 0.002) at 24 h, 46.1 ± 17.0 mg/dl at 48 h and 39.7 ± 13.5 mg/dl at 72 h. There was no mortality due to hyperphosphatemia. Sevelamer is efficacious in children with malignancy-associated hyperphosphatemia in the developing world.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11

    Article  PubMed  Google Scholar 

  2. Schucker JJ, Ward KE (2005) Hyperphosphatemia and phosphate binders. Am J Health Syst Pharm 62:2355–2361

    Article  CAS  PubMed  Google Scholar 

  3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607–617

    Article  CAS  PubMed  Google Scholar 

  4. Sedman A (1992) Aluminum toxicity in childhood. Pediatr Nephrol 6:383–393

    Article  CAS  PubMed  Google Scholar 

  5. Pieper AK, Haffner D, Hoppe B et al (2006) A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis 47:625–635

    Article  CAS  PubMed  Google Scholar 

  6. Chertow GM, Burke SK, Lazarus JM et al (1997) Poly [allylamina hydrochloride] (Renagel): a non-calcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66–71

    Article  CAS  PubMed  Google Scholar 

  7. Mahdavi H, Kuizon BD, Gales B et al (2003) Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Paediatr Nephrol 18:1260–1264

    Article  Google Scholar 

  8. Lo SF (2011) Reference intervals for laboratory tests and procedures. In: Kliegman RM, Stanton BMD, Geme JS, Schor N, Behrman RE (eds) Nelson textbook of pediatrics, vol 708, 19th edn. Saunders, Philadelphia

    Google Scholar 

  9. Kulkarni KP, Marwaha RK, Trehan A, Bansal D (2009) Survival outcome in childhood ALL: experience from a tertiary care centre in North India. Pediatr Blood Cancer 53:168–173

    Article  CAS  PubMed  Google Scholar 

  10. Abdullah S, Diezi M, Sung L et al (2008) Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children. Pediatric Blood Cancer 51:59–61

    Article  PubMed  Google Scholar 

  11. Yadav SP, Dua V, Sachdeva A (2011) Sepsis is a major barrier to improving survival in childhood acute lymphoblastic leukemia in the developing world. J Pediatr Hematol Oncol 33(8):636

    Article  PubMed  Google Scholar 

  12. Ramzan M, Yadav SP, Gupta D, Arora S, Sachdeva A (2012) Pediatric intensive care unit: an essential service to improve survival of childhood cancer in developing world. Indian J Pediatr 79(12):1669–1670

    Article  PubMed  Google Scholar 

  13. Runowski D, Jachimiak B, Cieślak-Puchalska A et al (2009) The use of sevelamer in the treatment of resistant hyperphosphatemia in children with chronic renal disease. Pol Merkur Lekarski 26(154):318–321

    PubMed  Google Scholar 

  14. Pui C-H, Jeha S, Irwin D, Camitta B (2001) Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 15:1505–1509

    Article  CAS  PubMed  Google Scholar 

  15. Capitanini A, Lupi A, Osteri F et al (2005) Gastric pH, sevelamer hydrochloride and omeprazole. Clin Nephrol 64:320–322

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Hemato-Oncology and Bone Marrow Transplant Unit, Sir Ganga Ram Hospital, New Delhi, India

    Dilraj Kaur Kahlon, Veronique Dinand, Satya Prakash Yadav & Anupam Sachdeva

  2. Pediatric Hemato-Oncology and Bone Marrow Transplant Unit, Fortis Memorial Research Institute, Gurgaon, 122002, Haryana, India

    Satya Prakash Yadav

Authors
  1. Dilraj Kaur Kahlon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Veronique Dinand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satya Prakash Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anupam Sachdeva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satya Prakash Yadav.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kahlon, D.K., Dinand, V., Yadav, S.P. et al. Sevelamer is an Effective Drug in Treating Hyperphosphatemia Due to Tumor Lysis Syndrome in Children: A Developing World Experience. Indian J Hematol Blood Transfus 32, 78–82 (2016). https://doi.org/10.1007/s12288-014-0481-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-014-0481-2

Keywords

Search

Navigation